In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts

Biotech enterprises, driven by the dual goals of treating a maximum patient population and ensuring a robust return on investment, must strategically navigate the complex landscape of global commercialization. Although the United States remains a crucial first market, most industry commentators agree that a nuanced strategy prioritizing global expansion is imperative. From a market size perspective, McKinsey’s assertion¹ that 35% of revenue from globally launched products emanates from markets beyond the U.S. aligns seamlessly with IQVIA’s data² on new medicine sales from 2016 to 2021.

Embarking on the journey as a chief commercial officer (CCO) or a chief global product strategy officer of a biotech or pharma company can be a daunting task, where the challenges are as invigorating as the rewards. Navigating the complexities of launching a medicinal product in a single country demands strategic prowess, yet the intricacies multiply exponentially when the goal is a simultaneous launch across multiple nations. Drawing upon his extensive experience as a seasoned CCO, Mr. Jenne has gleaned invaluable insights into the optimal practices for orchestrating global launches – a remarkable achievement that demands not just ambition, but also a deep understanding of the nuanced dynamics within diverse markets.

Kyle Jenne is Ionis’ executive vice president and chief global product strategy officer. He has more than 25 years of biopharmaceutical experience launching and commercializing innovative medicines in the U.S. and globally. He has broad relevant experience in rare, specialty and common diseases across therapeutic areas, including cardiovascular, neurology and allergy. Drawing upon his extensive experience as a seasoned CCO, Mr. Jenne has gleaned invaluable insights into the optimal practices for orchestrating global launches – a remarkable achievement that demands not just just ambition, but also a deep understanding of the nuanced dynamics within diverse markets.

COMPLETE THE FORM BELOW TO DOWNLOAD THE FULL Q&A WITH KYLE.

REFERENCES

¹ McKinsey & Company. (2022, March 23). Building a Global Biotech: Taking a First Time Launch into International Markets. McKinsey & Company. https://www.mckinsey.com/industries/life-sciences/our-insights/building-a-global-biotech-taking-a-first-time-launch-into-international-markets
² EFPIA. (2022). The Pharmaceutical Industry in Figures 2022. https://www.efpia.eu/media/637143/the-pharmaceutical-industry-in-figures-2022.pdf